Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Cleveland Biolabs logo — company profile

Cleveland Biolabs

Founded 2003 United States Buffalo, United States 21 employees Post Ipo Equity Total: $111.10M Biotechnology, Health Care

General Information

Company Name Cleveland Biolabs
Founded Year 2003
Location United States Buffalo, United States +1
Founders / Decision Makers
Team member
Employees 21
Industries Biotechnology, Health Care
Funding Stage Post Ipo Equity
Social

Get notified when Cleveland Biolabs moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Cleveland Biolabs

Cleveland BioLabs is a Clinical-stage biotechnology company focused on oncology and orphan drug development. Since its establishment in 2003, the company has been dedicated to the research, development, and commercialization of proprietary products targeting the potential treatment of cancer, prevention and treatment of acute radiation syndrome, and counteraction of the toxic effects of radio and chemotherapies for oncology patients. Presently, the company has nine product candidates in its pipeline being developed directly by them and their majority-owned subsidiaries, Incuron, LLC, and Panacela Labs, Inc. The company's focus on critical medical needs and its innovative approach to proprietary product development position it as a key player in the biotechnology and healthcare industries. Recently, Cleveland BioLabs received a significant $14.00M Post-IPO Equity investment on 19 February 2021. This investment reflects the confidence of investors in the potential of the company and its product pipeline. With its headquarters in the United States, Cleveland BioLabs continues to make strides in the development of crucial medical solutions, making it a compelling consideration for potential venture capital investments.

Taxonomy: oncology, drug development, clinical-stage, cancer treatment, radiation therapy, chemotherapy, acute radiation syndrome, orphan drugs, defense applications, tissue protection, proprietary products, clinical trials, majority-owned subsidiaries

Funding Rounds & Investors (12)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 19 Feb 2021
Post-IPO Equity •••••• - 01 Jun 2020
Post-IPO Equity •••••• 1
Investor
16 Aug 2018
Post-IPO Equity •••••• 1 •••• •••• 16 Jul 2015
Post-IPO Equity •••••• - 04 Feb 2015

View All 12 Funding Rounds

Cleveland Biolabs Alternatives & Competitors

Cleveland Biolabs vs
Alpha Cancer Technologies Inc.
Alpha Cancer Technologies Inc. Canada

HARNESSING NATURE TO BEAT CANCER

5 employees
Biotechnology, Pharmaceutical
Cleveland Biolabs vs
Cancer Care Specialist of Reno
Cancer Care Specialist of Reno United States

Highly Personalized and Precision Based Oncology and Hematology Care

36 employees
Health Care
Cleveland Biolabs vs
Yino
Yino

Advancing Oncology Radiotherapy with Pioneering Clinical Technology

Series C
IT, Information Technology

FAQ About Cleveland Biolabs

Cleveland BioLabs, Inc. (Nasdaq:CBLI) is a clinical-stage biotechnology company with a focus on oncology and orphan drug development. Since our inception in 2003, we have pursued the research, development and commercialization of proprietary products that have the potential to treat cancer, preve...
Cleveland Biolabs was founded in 2003.
Cleveland Biolabs is headquartered in Buffalo, United States.
Cleveland Biolabs operates in the following industries: Biotechnology, Health Care.
Cleveland Biolabs has approximately 21 employees.
Cleveland Biolabs has completed 12 funding rounds, raising a total of $111.10M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Cleveland Biolabs include Alpha Cancer Technologies Inc., Cancer Care Specialist of Reno, Yino, American Society for Radiation Oncology (ASTRO), Shenandoah Oncology. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Cleveland Biolabs and Alpha Cancer Technologies Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Cleveland Biolabs and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy